OakChart

NuCana plc ADR

NCNAHealthcare·Biotechnology·United Kingdom·Nano·NASD·Nov 11 • 3:59 PM ET

0.9398+0.0048 (0.51%)
2026-11-12 05:32 CET
Market cap
4.05 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-13.03 USD m
Free cash flow, TTM
-6.33 USD m
EPS diluted, TTM
-3.22
P/E
-
Compare

Price

NCNA against its 20, 50 and 200-day averages
2050200earnings
1.002.003.001.7M3.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NCNAclose 0.9420-day 0.9950-day 1.15200-day 1.660.94

79.3% under the 52-week high of 4.55 on 10 Dec 2025. 52-week low 0.90 on 11 Nov 2026. Last 15 sessions, 30.7% high to low

Volume 0.36× normal · the line is the 50-bar volume average

Profile

NCNA
52-week range, 1% of the way up
0.904.55

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Employees12
IPOSep 28, 2017
Beta2.43
ATR, 14d0.08
Rel volume0.36
Short float3.47%
Insider own6.99%
Inst own1.92%

Snapshot

6 groups

Valuation

Index-
Market Cap4.05M
Enterprise Value-20.95M
Income-13.03M
Sales0.00M
Book/sh0.04
Cash/sh6.01
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees12
IPOSep 28, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B25.07
P/C0.16
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio4.73
Current Ratio4.73
Debt/Eq0.03
LT Debt/Eq0.03
Option/ShortNo / Yes

Earnings

EPS (ttm)-3.22
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y83.42% 68.08%
Sales past 3/5Y- -
EPS Y/Y TTM99.50%
Sales Y/Y TTM-
EPS Q/Q96.76%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own6.99%
Insider Trans0.00%
Inst Own1.92%
Inst Trans-0.52%
ROA-46.15%
ROE-70.39%
ROIC-46.96%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-5.42%
SMA50-18.25%
SMA200-43.43%
Trades-

Technical

Shs Outstand4.31M
Shs Float4.01M
Short Float3.47%
Short Ratio1.20
Short Interest0.14M
52W High4.55 -79.35%
52W Low0.90 4.42%
Volatility6.32% 6.32%
ATR (14)0.08
RSI (14)38.00
Beta2.43
Rel Volume0.36
Avg Volume116.33K
Volume41,646

Performance

Perf Week-7.86%
Perf Month-10.50%
Perf Quarter-36.50%
Perf Half Y-49.74%
Perf YTD-73.89%
Perf Year-74.74%
Perf 3Y-99.95%
Perf 5Y-99.99%
Perf 10Y-
Recom3.00
Target Price4750.48
Prev Close0.94
Price0.94
Change %0.51%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Aug 30, 2024DowngradeWWilliam BlairOutperform → Mkt Perform
Mar 03, 2022DowngradeCCowenOutperform → Market Perform
Oct 22, 2020InitiatedTTruistBuy$22+2,240.9%
Jul 24, 2020InitiatedOOppenheimerOutperform
Aug 19, 2019InitiatedHH.C. WainwrightBuy$20+2,028.1%
Oct 19, 2018InitiatedPPiper JaffrayOverweight
Oct 23, 2017InitiatedWWilliam BlairOutperform
Oct 23, 2017InitiatedJJefferiesBuy$25+2,560.1%
Oct 23, 2017InitiatedCCitigroupBuy$23+2,347.3%

Peers

Mkt cap
TickerCompanyMkt cap
PCSAProcessa Pharmaceuticals Inc5.23M
MBRXMoleculin Biotech Inc8.50M
PPCBPropanc Biopharma Inc1.90M
ACTUActuate Therapeutics Inc16.63M
BYSIBeyondSpring Inc26.48M
SLXNSilexion Therapeutics Corp2.04M
ATNMActinium Pharmaceuticals Inc49.99M
CRDFCardiff Oncology Inc59.54M
KZIAKazia Therapeutics Limited ADR84.92M
BDRXBiodexa Pharmaceuticals Plc ADR1.25M

News

latest 14 of 200
  • NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe (GlobeNewswire) +11.57%
  • NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +7.43%
  • NuCana Appoints Ian Webster as Chief Financial Officer (GlobeNewswire) -6.87%
  • NuCana Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +5.88% +10.10%
  • NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update (GlobeNewswire)
  • NuCana Appoints Theresa Bruce as Chief Operating Officer (GlobeNewswire)
  • NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma (GlobeNewswire)
  • NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -7.92%
  • NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China (GlobeNewswire)
  • NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 (GlobeNewswire)
  • NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy (GlobeNewswire)
  • NuCana Compliant with All Nasdaq Continued Listing Criteria (GlobeNewswire)
  • NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025 (GlobeNewswire)
  • NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -12.64% +6.43%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-130.000--5.3110.00--
2026Q12026-05-140.000--1.2800.00--
2025Q42026-03-190.000--0.7980.00--
2025Q32025-11-130.000--0.1350.00--
2025Q22025-08-200.000--31.1060.00--
2024Q42025-03-20-2.600-19.320-29.5410.000.001
2024Q32024-11-25-17.640-201.14-485.360.000.003
2024Q22024-08-15-30.860-14.680-778.880.000.003
2024Q12024-05-16-0.320-6.920-809.140.000.004
2023Q42024-03-20-8.920-6.480-906.660.000.004
2023Q32023-11-16-8.060-6.100-804.410.000.004
2023Q22023-08-16-6.360-8.280-646.60.000.004
2023Q12023-05-17-9.500-7.000-912.440.000.003
2022Q42023-04-04-18.000-7.500-3,6170.000.004
2022Q32022-11-16-5.500-6.500-510.170.000.005
2022Q22022-08-17-4.000-7.500-472.880.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY-62.500-9.500-4,7470.000.00
2018FY-28.000-28.500-2,8860.000.00
2019FY-42.500-37.500-4,2250.000.00
2020FY-56.000-46.500-5,1930.000.00
2021FY-48.500-46.000-5,3560.000.00
2022FY-38.040-27.700-3,7760.000.00
2023FY-33.920-31.460-3,2670.000.00
2024FY-67.420-103.68-1,6360.000.00
2025FY0.000--33.0990.00-
2026FY--10.380--0.00
2027FY--67.420--0.00
2028FY--145.22--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q1S2025-04-231000.000.000.00
2026Q1S2025-04-221000.000.000.00
2026Q1S2025-04-211000.000.000.00
2026Q1S2025-04-201000.000.000.00
2026Q1S2025-04-191000.000.000.00
2026Q1S2025-04-181000.000.000.00
2026Q1S2025-04-171000.000.000.00
2026Q1S2025-04-161000.000.000.00
2026Q1S2025-04-151000.000.000.00
2026Q1S2025-04-141000.000.000.00
2026Q1S2025-04-131000.000.000.00
2026Q1S2025-04-121000.000.000.00
2026Q1S2025-04-111000.000.000.00
2026Q1S2025-04-101000.000.000.00

Estimate history

EPS, annual-4747.427-2886.021-4224.992-5193.152-5355.915-3775.529-3266.678-1635.983-17.199-3.2195
Period201720182019202020212022202320242025TTM
EPS, quarterly-778.884-485.361-29.541-102.571-31.106-0.135-0.798-1.28-1.007
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0060.0060.0060.010.010.010.010.0284.1624.31
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0110.020.0280.031.9084.1624.1624.1624.31
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.370.360.670.710.901.301.140.920.49
Gross Profit-0.37-0.36-0.67-0.71-0.90-1.30-1.14-0.92-0.49
Selling, General and Administrative Excl. Other19.2827.0728.7137.9452.9261.0741.0831.8228.88
Research and Development12.5916.7923.0231.1544.8750.6633.2125.1722.46
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-19.65-27.43-29.37-38.65-53.82-62.36-42.22-32.74-29.37
Interest Expense-0.030.020.040.030.020.030.030.00
Unusual Expense0.0016.670.040.630.363.860.000.000.00
Net Income Before Taxes-14.68-40.22-28.69-39.81-47.37-65.74-46.39-32.72-24.09
Income Taxes-1.65-1.54-4.41-5.47-7.92-10.00-7.04-5.41-5.63
Consolidated Net Income-13.03-38.68-24.27-34.35-39.44-55.75-39.35-27.32-18.45
Net Income From Continuing Operations-13.03-38.68-24.27-34.35-39.44-55.75-39.35-27.32-18.45
Net Income-13.03-38.68-24.27-34.35-39.44-55.75-39.35-27.32-18.45
EPS (Recurring)-3.11-12.03-1,633.96-3,225.07-3,751.42-5,096.07-5,193.13-4,224.97-2,886.01
EPS (Basic, Before Extraordinaries)-3.22-17.20-1,635.98-3,266.68-3,775.53-5,355.91-5,193.15-4,224.99-2,886.02
EPS (Diluted)-3.22-17.20-1,635.98-3,266.68-3,775.53-5,355.91-5,193.15-4,224.99-2,886.02
EBITDA-19.28-27.07-28.71-37.94-52.92-61.07-41.08-31.82-28.88
Non-Operating Income (Expense)4.973.900.75-0.506.840.51-4.140.045.29
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.789.911.583.604.887.424.473.331.94
Shares Outstanding4.314.160.030.010.010.010.010.010.01
Market Capitalization4.054.056.7415.4734.12123.00227.53195.07460.03

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.100.090.090.090.090.080.150.18
Gross Profit-0.10-0.09-0.09-0.09-0.09-0.08-0.15-0.18
Selling, General and Administrative Excl. Other4.526.353.694.7215.433.431.486.45
Research and Development3.024.332.312.939.482.170.934.86
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.61-6.44-3.78-4.82-15.52-3.52-1.63-6.62
Unusual Expense0.000.000.000.0016.890.000.040.00
Net Income Before Taxes-4.58-5.76-3.49-0.84-32.63-3.56-1.01-6.83
Income Taxes-0.45-0.55-0.19-0.47-0.44-0.44-0.18-0.96
Consolidated Net Income-4.13-5.21-3.30-0.38-32.19-3.11-0.84-5.86
Net Income From Continuing Operations-4.13-5.21-3.30-0.38-32.19-3.11-0.84-5.86
Net Income-4.13-5.21-3.30-0.38-32.19-3.11-0.84-5.86
EPS (Recurring)-0.99-1.25-0.79-0.10-19.69-102.58-28.52-485.33
EPS (Basic, Before Extraordinaries)-1.01-1.28-0.80-0.13-31.11-102.57-29.54-485.36
EPS (Diluted)-1.01-1.28-0.80-0.13-31.11-102.57-29.54-485.36
EBITDA-4.52-6.35-3.69-4.72-15.43-3.43-1.48-6.45
Non-Operating Income (Expense)0.030.680.293.97-0.22-0.040.66-0.20
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.911.910.881.077.840.24-0.020.37
Shares Outstanding4.314.164.164.161.910.030.030.02
Market Capitalization4.055.8314.988.8521.905.296.749.03

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments32.628.4521.9650.4281.62119.4168.8498.03117.29
Short Term Receivables2.515.817.438.4411.1114.5612.026.136.46
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.001.102.517.214.275.205.462.293.38
Total Current Assets36.1315.3631.8966.0697.00139.1686.31106.46127.13
Net Property, Plant & Equipment0.890.250.661.041.151.631.470.540.48
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets2.962.752.712.843.266.505.253.982.62
Deferred Tax Assets0.160.140.180.120.080.060.060.060.11
Other Assets0.000.000.000.003.440.000.000.000.00
Total Assets40.1318.5035.4570.07104.93147.3593.09111.04130.34
Short Term Debt Incl. Current Port. of LT Debt0.030.090.260.290.280.380.360.000.00
Accounts Payable0.000.000.000.000.000.000.000.000.00
Other Current Liabilities6.4210.7615.9022.9415.5910.767.837.093.95
Total Current Liabilities6.4510.8516.1623.2315.8711.148.197.093.95
Long Term Debt0.880.150.240.480.220.500.710.000.00
Provision for Risks Charges0.080.050.070.060.060.060.030.030.02
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities7.4111.0516.4823.7616.1511.708.947.123.97
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity32.727.4618.9846.3188.78135.6484.15103.92126.37
Total Shareholders Equity32.727.4618.9846.3188.78135.6484.15103.92126.37
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity32.727.4618.9846.3188.78135.6484.15103.92126.37
Total Liabilities & Stockholders Equity40.1318.5035.4570.07104.93147.3593.09111.04130.34
Book Value Per Share4.56263.421,812.244,464.198,589.5413,383.6913,157.3416,377.2020,180.34
Tangible Book Value Per Share7.15166.131,553.204,189.978,273.7312,742.6212,337.1015,750.5719,761.70
Full-Time Employees1222283133293124-
Price to Book Ratio25.070.900.580.581.391.682.324.4311.39
Return on Assets-131.96-89.98-65.10-45.08-44.19-32.73-26.76-15.29-36.26
Return on Equity-192.56-183.66-105.21-58.39-49.68-35.80-29.05-16.03-37.74
Return on Invested Capital-115.12-319.26-178.71-84.30-62.63-28.90-32.19-17.76-23.52
Quick Ratio5.601.421.972.846.1112.4910.5415.0232.22
Current Ratio5.601.421.972.846.1112.4910.5415.0232.22

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-13.81-38.68-24.27-34.35-39.44-55.75-39.35-27.32-18.45
Depreciation0.370.360.670.710.901.301.140.920.49
Other Funds (Non Cash)8.4833.802.403.386.2216.198.390.10-1.72
Funds from Operations-4.94-4.54-21.16-30.32-32.33-38.26-29.81-26.30-19.63
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.39-4.84-2.79-1.594.595.632.50-2.684.63
Cash from Operating Activities-6.33-9.38-23.95-31.91-27.74-32.63-27.31-28.98-15.00
Capital Expenditures-0.28-0.25-0.37-0.59-0.64-1.46-2.09-1.61-2.17
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.00-3.570.000.000.00
Other Sources0.000.000.003.230.000.000.000.000.00
Cash from Investing Activities-0.28-0.25-0.372.63-0.64-5.04-2.09-1.61-2.17
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock24.1036.5310.740.270.080.2779.630.160.28
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock24.1036.5310.740.270.080.2779.630.160.28
Proceedsfrom Stock Options23.8224.8310.730.260.000.00-5.770.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-3.51-3.500.000.000.000.000.000.030.00
Other Financing Activities Uses-3.51-3.500.000.000.000.000.000.000.00
Cash from Financing Activities20.5332.9610.46-0.07-0.20-0.1379.25-0.060.28
Exchange Rate Effect0.67-0.260.48-1.355.970.54-4.45-1.263.92
Net Change in Cash14.5923.07-13.39-30.69-22.61-37.2645.39-31.91-12.98
Free Cash Flow-6.33-9.38-23.96-31.91-27.75-32.71-27.78-29.04-15.28
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit--0.020.04-0.060.000.000.000.000.05

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments25.8928.3932.6233.9911.575.10
Short Term Receivables3.322.862.512.175.855.09
Inventories0.000.000.000.000.000.00
Other Current Assets1.101.151.004.011.401.58
Total Current Assets30.3032.4036.1340.1718.8111.77
Net Property, Plant & Equipment0.830.850.890.210.240.23
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets2.932.932.962.963.012.83
Deferred Tax Assets0.170.160.160.170.150.15
Other Assets0.000.000.000.000.000.00
Total Assets34.2236.3340.1343.5022.2214.97
Short Term Debt Incl. Current Port. of LT Debt0.050.040.030.100.100.10
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities6.365.876.428.3411.829.32
Total Current Liabilities6.415.916.458.4411.929.41
Long Term Debt0.850.850.880.080.110.13
Provision for Risks Charges0.080.080.080.080.080.05
Other Liabilities0.000.000.000.000.000.00
Total Liabilities7.336.847.418.6012.119.59
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity26.8929.5032.7234.9010.125.39
Total Shareholders Equity26.8929.5032.7234.9010.125.39
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity26.8929.5032.7234.9010.125.39
Total Liabilities & Stockholders Equity34.2236.3340.1343.5022.2214.97
Book Value Per Share0.044.114.564.872.06177.90
Tangible Book Value Per Share5.566.387.157.683.7284.52
Full-Time Employees--12---
Price to Book Ratio25.070.310.742.255.580.98
Return on Assets-46.15-160.15-133.00-104.79-176.52-80.52
Return on Equity-70.39-235.55-194.09-179.32-563.02-205.04
Return on Invested Capital-14.91-17.16-9.83-1.08-314.78-56.47
Quick Ratio4.735.485.604.761.581.25
Current Ratio4.735.485.604.761.581.25

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.12-5.21-3.18-1.31-31.23-3.11
Depreciation0.090.090.090.100.090.08
Other Funds (Non Cash)0.941.500.855.1926.591.28
Funds from Operations-3.09-3.61-2.213.97-4.56-1.76
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.51-0.470.96-2.39-1.30-2.12
Cash from Operating Activities-2.57-4.09-1.251.58-5.86-3.88
Capital Expenditures-0.05-0.10-0.07-0.07-0.07-0.05
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.05-0.10-0.07-0.07-0.07-0.05
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.100.00-0.1124.1112.080.58
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.100.00-0.1124.1112.080.58
Proceedsfrom Stock Options0.100.00-0.0823.800.620.58
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.01-3.520.000.00
Other Financing Activities Uses0.000.000.01-3.520.000.00
Cash from Financing Activities0.07-0.01-0.0920.5612.050.56
Exchange Rate Effect-0.160.530.020.28-0.41-0.15
Net Change in Cash-2.71-3.67-1.3922.365.71-3.52
Free Cash Flow-2.57-4.09-1.251.58-5.86-3.88

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.47%0.1M4.0M119.27K
2026-10-153.62%0.1M4.0M119.32K
2026-09-302.49%0.1M4.0M110.65K
2026-09-152.67%0.1M4.0M62.48K
2026-08-313.96%0.2M4.0M64.23K
2026-08-143.35%0.1M4.0M50.51K
2026-07-313.78%0.1M3.9M49.61K
2026-07-154.51%0.2M3.9M49.10K
2026-06-302.99%0.1M3.9M42.28K
2026-06-153.38%0.1M3.9M44.71K
2026-05-293.29%0.1M3.9M44.17K
2026-05-154.32%0.2M3.9M42.14K
2026-04-304.37%0.2M3.9M42.85K
2026-04-154.37%0.2M3.9M53.20K
2026-03-314.35%0.2M3.9M61.17K
2026-03-134.13%0.2M3.9M62.34K
2026-02-274.56%0.2M3.9M63.36K
2026-02-134.86%0.2M3.9M70.63K
2026-01-305.48%0.2M3.9M74.11K
2026-01-155.07%0.2M3.9M117.54K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-19SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-19SEC
2026-06-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-08SEC
2026-06-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-01SEC
2026-05-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-14SEC
2026-05-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-06SEC
2026-04-164Statement of changes in beneficial ownership of securities2026-04-15SEC
2026-04-013Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-243Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-203Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-193Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-19S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-1920-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-19SEC
2026-03-18SCHEDULE 13DSEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-01-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-06SEC
2025-12-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-17SEC
2025-12-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-10SEC
2025-11-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-13SEC
2025-11-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-05SEC
2025-10-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-10-20SEC
2025-10-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-10-14SEC
2025-09-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-09-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
CITADEL ADVISORS LLC0.65%
HRT FINANCIAL LP0.41%
StoneX Group Inc.0.40%
Glass Jacobson Investment Advisors llc0.35%
RHUMBLINE ADVISERS0.11%
CITIGROUP INC0.03%
Nuveen, LLC0.01%
Caitong International Asset Management Co., Ltd0.00%
MORGAN STANLEY0.00%
ACADIAN ASSET MANAGEMENT LLC0.00%

Funds

Fund% owned
Blackstone Alternative Multi-Strategy Fund-0.01%

OakChart. NCNA. Cached 15 minutes.

Some panels did not load: insider.